Equasens Société anonyme Management
Management criteria checks 2/4
Equasens Société anonyme's CEO is Denis Supplisson, appointed in Apr 2022, has a tenure of 2.67 years. directly owns 0% of the company’s shares, worth €465.59. The average tenure of the management team and the board of directors is 1.9 years and 13 years respectively.
Key information
Denis Supplisson
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.7yrs |
| CEO ownership | 0.00007% |
| Management average tenure | 1.9yrs |
| Board average tenure | 13yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | €42m |
| Mar 31 2024 | n/a | n/a | €45m |
| Dec 31 2023 | n/a | n/a | €47m |
| Jun 30 2023 | n/a | n/a | €48m |
| Mar 31 2023 | n/a | n/a | €47m |
| Dec 31 2022 | €400k | €176k | €46m |
| Jun 30 2022 | n/a | n/a | €42m |
| Mar 31 2022 | n/a | n/a | €41m |
| Dec 31 2021 | €353k | €133k | €39m |
| Sep 30 2021 | n/a | n/a | €37m |
| Jun 30 2021 | n/a | n/a | €35m |
| Mar 31 2021 | n/a | n/a | €33m |
| Dec 31 2020 | €371k | €133k | €31m |
| Sep 30 2020 | n/a | n/a | €29m |
| Jun 30 2020 | n/a | n/a | €27m |
| Mar 31 2020 | n/a | n/a | €27m |
| Dec 31 2019 | €225k | €133k | €27m |
| Sep 30 2019 | n/a | n/a | €27m |
| Jun 30 2019 | n/a | n/a | €26m |
| Mar 31 2019 | n/a | n/a | €26m |
| Dec 31 2018 | €208k | €128k | €25m |
| Sep 30 2018 | n/a | n/a | €25m |
| Jun 30 2018 | n/a | n/a | €24m |
| Mar 31 2018 | n/a | n/a | €24m |
| Dec 31 2017 | €189k | €114k | €23m |
Compensation vs Market: Insufficient data to establish whether Denis's total compensation is reasonable compared to companies of similar size in the German market.
Compensation vs Earnings: Denis's compensation has been consistent with company performance over the past year.
CEO
Denis Supplisson (55 yo)
2.7yrs
Tenure
€400,201
Compensation
Mr. Denis Supplisson serves as Chief Executive Officer at Pharmagest Interactive SA since April 22, 2022. He served as Deputy Managing Director/Deputy Chief Executive Officer & Manager of the Europe Pharma...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman of the Board | 14.9yrs | no data | 0.036% € 237.2k | |
| Deputy CEO | 4.4yrs | €428.66k | 0.000070% € 465.6 | |
| Chief Executive Officer & Director | 2.7yrs | €400.20k | 0.000070% € 465.6 | |
| Director | no data | €330.17k | 0.16% € 1.1m | |
| Group Chief Administrative & Financial Officer | 1.9yrs | no data | no data | |
| Head of Communications | less than a year | no data | no data | |
| Chief Human Resources Officer | 5.2yrs | no data | no data | |
| Head of the Medical Solutions Division | less than a year | no data | no data | |
| Deputy MD & Head of the Pharmagest Division | less than a year | no data | no data |
1.9yrs
Average Tenure
55yo
Average Age
Experienced Management: PHF's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman of the Board | 14.9yrs | no data | 0.036% € 237.2k | |
| Deputy CEO | 4.4yrs | €428.66k | 0.000070% € 465.6 | |
| Chief Executive Officer & Director | 11.9yrs | €400.20k | 0.000070% € 465.6 | |
| Director | 15.5yrs | €330.17k | 0.16% € 1.1m | |
| Director | 22.6yrs | €6.91k | 0.0033% € 22.1k | |
| Director | 13.9yrs | no data | no data | |
| Director | 13.9yrs | €7.07k | 0.0027% € 18.3k | |
| Director | 13.5yrs | no data | 0.0046% € 30.5k | |
| Independent Director | 12.5yrs | €6.76k | 0.00017% € 1.1k | |
| Independent Director | 7.5yrs | €6.91k | 0.00013% € 864.7 | |
| Director | 7.5yrs | €604.00 | 0.00011% € 731.6 | |
| Independent Director | 1.5yrs | no data | 0.000010% € 66.5 |
13.0yrs
Average Tenure
57.5yo
Average Age
Experienced Board: PHF's board of directors are seasoned and experienced ( 13 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 12:51 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Equasens Société anonyme is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jean-Baptiste Bouchet | CIC Market Solutions (ESN) |
| Robin Leclerc | Degroof Petercam |
| Yann de Peyrelongue | Gilbert Dupont |